Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology
- PMID: 16094559
Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology
Abstract
The in vitro activity of tulathromycin was evaluated against common bovine and porcine respiratory pathogens collected from outbreaks of clinical disease across eight European countries from 1998 to 2001. Minimum inhibitory concentrations (MICs) for one isolate of each bacterial species from each outbreak were determined using a broth microdilution technique. The lowest concentrations inhibiting the growth of 90% of isolates (MIC90) for tulathromycin were 2 microg/ml for Mannheimia (Pasteurella) haemolytica, 1 microg/ml for Pasteurella multocida (bovine), and 2 microg/ml for Pasteurella multocida (porcine) and ranged from 0.5 to 4 microg/ml for Histophilus somni (Haemophilus somnus) and from 4 to 16 microg/ml for Actinobacillus pleuropneumoniae. Isolates were retested in the presence of serum. The activity of tulathromycin against fastidious organisms was affected by culture conditions, and MICs were reduced in the presence of serum.
Similar articles
-
Susceptibility testing of tulathromycin: interpretative breakpoints and susceptibility of field isolates.Vet Microbiol. 2008 Jun 22;129(3-4):426-32. doi: 10.1016/j.vetmic.2007.11.033. Epub 2007 Dec 4. Vet Microbiol. 2008. PMID: 18187275
-
Efficacy of tulathromycin in the treatment and prevention of natural outbreaks of bovine respiratory disease in European cattle.Vet Ther. 2005 Summer;6(2):122-35. Vet Ther. 2005. PMID: 16094560 Clinical Trial.
-
Efficacy of tulathromycin injectable solution for the treatment of naturally occurring Swine respiratory disease.Vet Ther. 2005 Summer;6(2):214-24. Vet Ther. 2005. PMID: 16094568 Clinical Trial.
-
Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease.Vet Ther. 2005 Summer;6(2):83-95. Vet Ther. 2005. PMID: 16094557 Review.
-
The role of the macrolide tulathromycin in veterinary medicine.Vet J. 2013 Nov;198(2):352-7. doi: 10.1016/j.tvjl.2013.07.032. Epub 2013 Aug 6. Vet J. 2013. PMID: 24268476 Review.
Cited by
-
Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against Actinobacillus pleuropneumoniae in a Porcine Tissue Cage Infection Model.Front Vet Sci. 2022 Mar 28;9:822432. doi: 10.3389/fvets.2022.822432. eCollection 2022. Front Vet Sci. 2022. PMID: 35419449 Free PMC article.
-
Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.PLoS One. 2018 Dec 31;13(12):e0209177. doi: 10.1371/journal.pone.0209177. eCollection 2018. PLoS One. 2018. PMID: 30596709 Free PMC article.
-
An evaluation of the relative efficacy of tulathromycin for the treatment of undifferentiated fever in feedlot calves in Nebraska.Can Vet J. 2007 Jun;48(6):600-6. Can Vet J. 2007. PMID: 17616056 Free PMC article. Clinical Trial.
-
Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China.Pathogens. 2021 Jan 22;10(2):105. doi: 10.3390/pathogens10020105. Pathogens. 2021. PMID: 33498972 Free PMC article.
-
The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.Oncotarget. 2017 Dec 7;9(2):1673-1690. doi: 10.18632/oncotarget.23018. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416722 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical